Dual-Stage Picolinic Acid-Derived Inhibitors of Toxoplasma gondii.

ABSTRACT: Toxoplasma gondii causes a prevalent human infection for which only the acute stage has an FDA-approved therapy. To find inhibitors of both the acute stage parasites and the persistent cyst stage that causes a chronic infection, we repurposed a compound library containing known inhibitors of parasitic hexokinase, the first step in the glycolysis pathway, along with a larger collection of new structural derivatives. The focused screen of 22 compounds showed a 77% hit rate (>50% multistage inhibition) and revealed a series of aminobenzamide-linked picolinic acids with submicromolar potency against both T. gondii parasite forms. Picolinic acid 23, designed from an antiparasitic benzamidobenzoic acid class with challenging ADME properties, showed 60-fold-enhanced solubilit

SUBMITTER: Khalifa MM 

PROVIDER: S-EPMC7734631 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature